Sonoma Pharmaceuticals Inc (SNOA) News

SNOA .36

SNOA hit .24

SNOA...........................https://stockcharts.com/h-sc/ui?s=SNOA&p=W&b=5&g=0&id=p86431144783

Upcoming Events ---->
https://sonomapharma.com/sonoma-events-tradeshows/

GO $SNOA

Investor Presentation From April 9, 2024 ---->
https://d1io3yog0oux5.cloudfront.net/_f4a411dced9e94f2fedfb7f057423722/sonomapharma/db/359/2900/pdf/Sonoma+Presentation+4.9.24+Website+Version.pdf

GO $SNOA

bottom

.16-.25

$1.7M OFFERING @ .20
https://dilutiontracker.com/app/search/SNOA

😁

SNOA new 52 week low

SNOA new 52 week low

SNOA new 52 week low

hmmm

nice

dip;

Coming back around Cool

nice

nice

SNOA: Hey, Cpt. T-N!!! (I indeed DID get your PM, but --- since I no longer have a subscription to that --- I can only reply to you right here. In any event, THANKS Bro for your heads-up!!)

And let's get this Big Dog FLYIN'!!!!

Continuing higher from PM

There is no other symbol. The other one is s private company.

$SNOA being confused with a different Sonoma regarding $REGN deal— t.k. (@tcarm1) March 28, 2023

The other is private company partnering with REGN

WHATS THE OTHER SYMBOL?

people chased off news from the WRONG TICKER...lol

https://finviz.com/quote.ashx?t=SNOA&p=d

Nice premarket gap up

Nice AH move

Sonoma Pharmaceuticals managed to land one serious new customer: the United States government. Sonoma’s Microcyn Rx line of products now have a DAPA, or a Distribution and Pricing Agreement. This opens up their use for the Defense Logistics Agency. This also gives Sonoma’s partner, EMC Pharma, the ability to offer Microcyn Rx products to its own customers in the U.S. government. Half of EMC Pharma’s customer base is U.S. government entities. That, in turn, likely means a nice shot in the profits for Sonoma’s partner firm.

OS only 3+milly

Buy 2’s up!

2.68 finally broke $2.44 without meeeeeeeeee

#ARRRRRRRRG

after taking it down to 1.88

im out with profits on the fail to break new ni

Good Morning $SNOA

break 2.44 run to 2.75+

trying again for 2.44

$SNOA watch for 2.44 break tried 2x already

$2.10 Ran to quick for me might have to pass unless it pulls back some 2.2 million float could do more wonders.
Good luck

$SNOA https://twitter.com/algobotnews/status/1618227346275794944

https://finviz.com/quote.ashx?t=SNOA&ty=c&ta=1&p=d

3M os lets see how it goes https://finviz.com/quote.ashx?t=SNOA&ty=c&ta=1&p=d

Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States
Download as PDFOctober 27, 2022
BOULDER, CO / ACCESSWIRE / October 27, 2022 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care and dermatological conditions, today announced that it has launched Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Advanced Skin Repair Cooling Mist direct to consumers for over-the-counter use in the United States.

Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel is a new direct to consumer version of a product previously only available by prescription. Reliefacyn alleviates symptoms such as red bumps, itchy, painful and scaly rashes, shallow skin fissures and peeling, and effectively manages symptoms of eczema/atopic dermatitis. Reliefacyn supports the three phases of healing (inflammation, proliferation and remodeling), and the gel adheres quickly to the skin, making it easy to apply without dripping or running. Reliefacyn is antipruritic, anti-inflammatory, and anti-allergic.

Rejuvacyn® Advanced Skin Repair Cooling Mist is intended for over-the-counter management of minor skin irritations following cosmetic procedures as well as daily skin health and hydration. Formulated to enhance the body's natural healing process, Rejuvacyn aids in recovery following common procedures performed at dermatologists' offices and medical spas such as microdermabrasion, laser treatments, injections, facials, and chemical peels. Rejuvacyn is safe to use around the nose, mouth, and eyes, with a cool mist application that soothes the skin. Rejuvacyn® Advanced Skin Repair Cooling Mist has also been certified as a Natural Personal Care Product by the Natural Products Association.

"We are excited to expand our line of dermatology products to create a portfolio of consumer-focused products that provide healing and relief for common conditions and procedures. We've also formulated Rejuvacyn as an all-natural product for consumers who want to avoid potentially harmful additives in their healthcare regime. Our products will be immediately available through our website, and through third-party distributors," said Amy Trombly, CEO of Sonoma Pharmaceuticals.

For more information about these products, visit https://sonomapharma.com/dermatology-new. You can order Reliefacyn or Rejuvacyn on our website at https://otc.sonomapharma.com or by contacting our customer service department at 720-452-9690 or customerservice@sonomapharma.com.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within

been a long time since i visited this board. but i'm still accumulating SNOA!!! hoping some news comes to do what it did last August !????????????????

lo floater on news .....

So,so news. No $ contracts announced. News catalyst for day trade.

does SNOA ran more on this hand sanitizer news, hold or fall back?

Going straight up!

$SNOA news is nothing special but the float already traded in premarket. Could be a serious squeeze here— M K (@pennystockpickz) October 15, 2021

I noticed your first on the scene for a lot of these runners. Congrats !

O/s 2.09m short float 39%

Could be a huge runner today

Sonoma Pharma, MicroSafe Report Nanocyn Disinfectant, Sanitzer Has Been Approved By Australia Therapeutic Goods Admin.
7:04 am ET October 15, 2021 (Benzinga) Print
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma’s patented Microcyn® Technology.

After original approval by the TGA and entry into The Australian Register Of Therapeutic Goods for use against SARS-CoV-2 (COVID 19) in mid-2020, the TGA has now approved extended claims for the hard-surface disinfectant Nanocyn® with a 15 second kill time against common viruses, including SARS-CoV-2, Norovirus (Gastro), and influenza, and a 30-second kill contact time against common bacteria, such as Staphylococcus aureus (MRSA), E. coli, Pseudomonas aeruginosa, fungi and mold - including Candida Albicans.

“Nanocyn® is a game-changer for any hospital, aged care or health care facility, transportation-provider, business, school, tourism or hospitality venue wanting to ensure their premises are COVID-safe, not just from a pandemic point of view, but also the comfort that comes with using a non-toxic disinfectant that does not leave any harmful residues behind,” said MicroSafe Group CEO Safa Qadumi.

In addition, Nanocyn® had been previously certified by major aviation manufacturers. The product can disinfect aircraft without damaging sensitive materials. It is also the only TGA registered hospital grade disinfectant of its kind to be certified by Good Environmental Choice Australia (GECA).

Bruce Thornton, Chief Operating Officer of Sonoma Pharmaceuticals stated, “We could not be more excited about making our safe and effective Microcyn® Technology available to valued partners such as MicroSafe. We are continuously seeking to add to our network of international distributors to increase the reach of Sonoma products worldwide.”